Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Innovent Biologics Raises $25 Million for Suzhou cGMP Facility

publication date: Nov 16, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Innovent Biologics, a Suzhou antibody development and manufacturing company, officially announced a $25 million Series B financing. The investors were Lilly Asia Ventures and two Fidelity funds: Fidelity Biosciences and Fidelity Growth Partners Asia. Innovent is using some of the new capital to build a new campus in Suzhou BioBay that will house monoclonal antibody lab and manufacturing facilities. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...